Skip to main
OCGN
OCGN logo

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is focused on developing innovative gene and cell therapies, with its pipeline highlighting significant advancements in treating retinal diseases through its modifier gene therapy platform. Positive prospects for the company's stock are bolstered by the promising efficacy and safety outcomes of its OCU400 in the ongoing Phase I/II clinical trial, along with the potential for lucrative collaboration agreements and mergers and acquisitions. These factors, combined with the company's commitment to addressing unmet medical needs, position Ocugen favorably for growth in the biotechnology sector.

Bears say

Ocugen's stock outlook appears negative due to several fundamental challenges, including its inability to secure necessary investment amid poor market conditions. The company has expressed concerns that a short timeline for Nasdaq compliance has hindered its financial position and growth potential. Furthermore, there is significant risk that emerging treatment methods for retinal diseases could render Ocugen's current therapies non-competitive or obsolete, impacting future revenues and market viability.

Ocugen, Inc. (OCGN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.